News & Press Releases

Bridge to Life Ltd. announced today its divestiture of certain assets to TransMedics, Inc., a wholly owned subsidiary of TransMedics Group, Inc., including its EVOSS heart and lung and LifeCradle heart perfusion assets.

Bridge to Life Ltd. announced results from interim analysis of its multicenter, randomized, controlled liver clinical trial presented at the 2023 American Transplant Congress (ATC).

Bridge to Life, Ltd. announced that it met positive criteria from interim analysis for early enrollment closure of its multicenter, randomized, controlled Bridge to HOPE Liver Clinical Trial.

Bridge to Life, Ltd. announced the expansion of their executive leadership team by appointing Bob Beechey as Chief Financial Officer and Blago Herrera as Vice President of Operations.

Bridge to Life, Ltd. announced early results from its multicenter, randomized, controlled Bridge to HOPE Liver Clinical Trial.

Steve Schweighardt, founder and former CEO to retire from daily operations but will remain as Chairman of the Board.

Bridge to Life advances their perfusion system development with the breakthrough device designation for the LifeCradle® Heart Preservation Transport system.

Bridge to Life Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, announced first enrollment and orthotopic liver transplantation in its U.S. pivotal Bridge to HOPE Liver Clinical Trial.

The primary endpoint for the trial is the rate of early allograft dysfunction between treatment groups; additional key endpoints include rates of ischemic cholangiopathy and patient and graft survival up to 1-year post-transplantation. 

Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, announced the first closing of a growth financing, totaling $56 million, led by Perceptive Advisors, a leading life sciences investment firm.

Bridge to Life Chairman & CEO Stevan Schweighardt was interviewed in a feature piece for CEOCFO Magazine. He discusses the challenges of the transplant field and Bridge to Life’s current and upcoming solutions to make organ transplantations more successful.

Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, and Tevosol, Inc., a clinical stage medical device startup, today announced their merger to develop and commercialize groundbreaking new products for the organ transplantation community. The arrangement includes Bridge to Life’s significant financial commitment to manufacture, trial, and launch Tevosol’s portable ex-vivo lung perfusion (EVLP) machine and normothermic organ preservation platform.

Bridge to Life is proud to have sponsored two webinars in the ILTS Insights series. Each webinar can be watched below.